Suppression of insulin feedback enhances the efficacy of PI3K inhibitors

[1]  Violena Pietrobon.  Cancer metabolism , 2021, Cell.

[2]  Lewis C. Cantley,et al.  The PI3K Pathway in Human Disease , 2017, Cell.

[3]  Davide Prandi,et al.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. , 2017, Cancer discovery.

[4]  J. Baselga,et al.  Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. , 2017, Cancer discovery.

[5]  Gunnar Rätsch,et al.  Prediction of ultra-potent shRNAs with a sequential classification algorithm , 2017, Nature Biotechnology.

[6]  P. Puchalska,et al.  Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. , 2017, Cell metabolism.

[7]  M. Pollak,et al.  Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? , 2017, Nature Reviews Clinical Oncology.

[8]  S. Ikeda,et al.  Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. , 2016, JAMA oncology.

[9]  L. Cantley,et al.  Obesity and Cancer Mechanisms: Cancer Metabolism. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Sampaio.  Ketogenic diet for epilepsy treatment. , 2016, Arquivos de neuro-psiquiatria.

[11]  F. Toledo,et al.  First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Han Wu,et al.  Association between markers of glucose metabolism and risk of colorectal cancer , 2016, BMJ Open.

[13]  E. Winer,et al.  A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer , 2016, Clinical Cancer Research.

[14]  M. Rubin,et al.  An emerging role for cytopathology in precision oncology , 2016, Cancer cytopathology.

[15]  L. Cantley,et al.  Adaptive changes in amino acid metabolism permit normal longevity in mice consuming a low-carbohydrate ketogenic diet. , 2015, Biochimica et biophysica acta.

[16]  Oleg Demin,et al.  Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model , 2014, Front. Pharmacol..

[17]  Guy Jerusalem,et al.  Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy , 2014, Clinical Cancer Research.

[18]  Christof Fellmann,et al.  An optimized microRNA backbone for effective single-copy RNAi. , 2013, Cell reports.

[19]  D. Leroith,et al.  Insulin and IGFs in Obesity-Related Breast Cancer , 2013, Journal of Mammary Gland Biology and Neoplasia.

[20]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[21]  William W. Agresti,et al.  Advancing the IT research agenda , 2013, RIIT '13.

[22]  M. Pollak.  Potential applications for biguanides in oncology. , 2013, The Journal of clinical investigation.

[23]  P. Pandolfi,et al.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.

[24]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Leroith,et al.  Minireview: IGF, Insulin, and Cancer. , 2011, Endocrinology.

[26]  M. Pollak.  Metformin and Other Biguanides in Oncology: Advancing the Research Agenda , 2010, Cancer Prevention Research.

[27]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[28]  M. Pfister,et al.  Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus , 2009, Clinical pharmacology and therapeutics.

[29]  M. Stampfer,et al.  Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. , 2008, The Lancet. Oncology.

[30]  T. Waldman,et al.  PTEN Gene Targeting Reveals a Radiation-Induced Size Checkpoint in Human Cancer Cells , 2004, Cancer Research.

[31]  M. Stampfer,et al.  A prospective study of plasma C-peptide and colorectal cancer risk in men. , 2004, Journal of the National Cancer Institute.